Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023
January 26, 2023 02:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, United States), January 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunie le 25 janvier 2023
January 26, 2023 02:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, Etats-Unis), le 26 janvier 2023 – Inventiva (Euronext Paris et Nasdaq : IVA), société́ biopharmaceutique spécialisée dans le développement clinique de...
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
February 25, 2022 07:00 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients
February 08, 2022 08:00 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 16:05 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment
November 12, 2021 08:01 ET
|
Akero Therapeutics
Most EFX-treated patients with end-of-treatment biopsies showed improvements in features of steatohepatitis (35 of 40; 87%) and/or fibrosis (32 of 40; 80%), after only 16 weeks Histological...
Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021 07:00 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
November 09, 2021 16:15 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
October 19, 2021 16:15 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...
Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference
October 05, 2021 08:00 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...